Journal article
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Abstract
Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This open-label randomized phase II study evaluated progression-free survival (PFS) with seribantumab in combination with once-per-week paclitaxel compared with paclitaxel alone in patients with …
Authors
Liu JF; Ray-Coquard I; Selle F; Poveda AM; Cibula D; Hirte H; Hilpert F; Raspagliesi F; Gladieff L; Harter P
Journal
Journal of Clinical Oncology, Vol. 34, No. 36, pp. 4345–4353
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
December 20, 2016
DOI
10.1200/jco.2016.67.1891
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansKaplan-Meier EstimateMiddle AgedNeoplasm InvasivenessNeoplasm StagingOvarian NeoplasmsPaclitaxelPrognosisProportional Hazards ModelsProspective StudiesRisk AssessmentSurvival AnalysisTreatment Outcome